Lumos Pharma Receives $34,000,000 Series B Round

  • Feed Type
  • Date
    4/6/2016
  • Company Name
    Lumos Pharma
  • Mailing Address
    4200 Marathon Blvd. Austin, TX 78756 USA
  • Company Description
    Lumos Pharma, based in Austin, Texas, is an early stage biotechnology company created to develop and commercialize a novel treatment for the rare disease Creatine Transporter Deficiency.
  • Website
    http://www.lumos-pharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $34,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Lumos will use the proceeds for clinical trials and commercialization of its lead compound, LUM-001, for the treatment of Creatine Transporter Deficiency (CTD). Funding will also be used to further develop other therapeutics in the company’s pipeline.
  • M&A Terms
  • Venture Investor
    Deerfield Capital
  • Venture Investor
    New Enterprise Associates
  • Venture Investor
    Sante Ventures
  • Venture Investor
    Clarus Ventures
  • Venture Investor
    Roche Venture Fund
  • Venture Investor
    UCB S.A.

Trending on Xconomy